<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03869619</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL18_0352</org_study_id>
    <secondary_id>2018-A01332-53</secondary_id>
    <nct_id>NCT03869619</nct_id>
  </id_info>
  <brief_title>REal World Data in LYmphoma and Survival in Adults</brief_title>
  <acronym>REALYSA</acronym>
  <official_title>REAL WORLD DATA IN LYMPHOMA AND SURVIVAL IN ADULTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Lymphoma Academic Research Organisation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      REALYSA cohort is a population-based epidemiological platform in real-life for lymphomas&#xD;
      designed to enrich prognostic data, by integrating together epidemiological, clinical and&#xD;
      biological data.&#xD;
&#xD;
      REALYSA is a platform perfectly set up to&#xD;
&#xD;
        -  Study prognostic factors using integrated epidemiological and biological data&#xD;
           (genetics), to better characterize the determinants of refractoriness and relapse in&#xD;
           patients with lymphoma, to follow the growing number of survivors and describe median to&#xD;
           long-term sequela, second cancer, quality of life (QoL)…&#xD;
&#xD;
        -  Document treatment effectiveness in real life and observance&#xD;
&#xD;
        -  Address socio-economical questions&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 14, 2018</start_date>
  <completion_date type="Anticipated">November 14, 2027</completion_date>
  <primary_completion_date type="Anticipated">November 14, 2027</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>9 Years</target_duration>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients included per month in total and according to subtype of lymphoma</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients in each region in total and according to subtype of lymphoma</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-Free Survival (EFS)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-Free Survival (EFS)</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net Survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net Survival</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Next Anti-Lymphoma Treatment (TTNLT)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Next Anti-Lymphoma Treatment (TTNLT)</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Survival after progression</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Survival after progression</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Lymphoma transformations</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Lymphoma transformations</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Second cancers</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Second cancers</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of other chronic disease</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of other chronic disease</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of exposure factors</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of comorbidities</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Representativeness of the included population</measure>
    <time_frame>5 years</time_frame>
    <description>Study population must show a good representativeness of the source population regarding demographic or diseases characteristics, to be able to generalize our results. Indeed, the representativeness of the study population can only be evaluated in areas covered by population-based cancer registries (PBCR) by comparing cases included in the REALYSA project to incident lymphoma cases registered in the general population (PBCR of the FRANCIM network).</description>
  </other_outcome>
  <other_outcome>
    <measure>Representativeness of the included population</measure>
    <time_frame>9 years</time_frame>
    <description>Study population must show a good representativeness of the source population regarding demographic or diseases characteristics, to be able to generalize our results. Indeed, the representativeness of the study population can only be evaluated in areas covered by population-based cancer registries (PBCR) by comparing cases included in the REALYSA project to incident lymphoma cases registered in the general population (PBCR of the FRANCIM network).</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">6000</enrollment>
  <condition>Diffuse Large B Lymphoma (DLBCL)</condition>
  <condition>Follicular Lymphoma (FL)</condition>
  <condition>Mantle Cell Lymphoma (MCL)</condition>
  <condition>Marginal Zone Lymphoma (MZL)</condition>
  <condition>T-cell Lymphoma (T-NHL)</condition>
  <condition>Hodgkin's Lymphoma (HL)</condition>
  <condition>Burkitt Lymphoma (BL))</condition>
  <arm_group>
    <arm_group_label>All enrolled patients</arm_group_label>
    <description>All patient who signed the consent form for participation to the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Real-life epidemiological platform of lymphoma in France</intervention_name>
    <description>The REALYSA database will be described with the following characteristics:&#xD;
Number of patients included per month in total and according to subtype of lymphoma&#xD;
Number of patients in each region in total and according to subtype of lymphoma</description>
    <arm_group_label>All enrolled patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with lymphoma in the last 6 months.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signature of the consent form for participation in the REALYSA cohort&#xD;
&#xD;
          -  Aged over 18 at the time of inclusion&#xD;
&#xD;
          -  Diagnosed with lymphoma in the last 6 months (180 days)&#xD;
&#xD;
          -  Lymphoma subtype belonging to at least one of the 7 histological subtypes: diffuse&#xD;
             large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone&#xD;
             lymphoma, T-cell lymphoma, Hodgkin's lymphoma, Burkitt lymphoma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anti-lymphoma treatment already received (except pre-phase: typically corticosteroids,&#xD;
             vincristine, cyclophosphamide, etoposide, alone or in combination)&#xD;
&#xD;
          -  Documented HIV infection&#xD;
&#xD;
          -  Any other lymphoma subtype not included in the list in Appendix 1. Of note, are&#xD;
             excluded:&#xD;
&#xD;
               -  Chronic lymphocytic leukemia/small lymphocytic lymphoma&#xD;
&#xD;
               -  Hairy cell leukemia and variant&#xD;
&#xD;
               -  Lymphoplasmacytic lymphoma&#xD;
&#xD;
               -  Waldenström macroglobulinemia&#xD;
&#xD;
               -  Primary DLBCL of the central nervous system (CNS)&#xD;
&#xD;
               -  T-cell large granular lymphocytic leukemia&#xD;
&#xD;
               -  Chronic lymphoproliferative disorder of NK cells&#xD;
&#xD;
               -  Mycosis fungoides&#xD;
&#xD;
               -  Sézary syndrome&#xD;
&#xD;
               -  Primary cutaneous T cell lymphomas (mainly diagnosed and treated by&#xD;
                  dermatologists)&#xD;
&#xD;
               -  Post-transplant lymphoproliferative disorders (PTLD)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hervé Ghesquières, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alain Monnereau, MD</last_name>
    <role>Study Director</role>
    <affiliation>Université de Bordeaux : Inserm</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hervé Ghesquières, MD</last_name>
    <phone>04 78 86 43 40</phone>
    <phone_ext>+33</phone_ext>
    <email>herve.ghesquieres@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alain Monnereau, MD</last_name>
    <phone>05 56 33 33 33</phone>
    <phone_ext>+33</phone_ext>
    <email>A.Monnereau@bordeaux.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Unité d'Hématologie Clinique, CH D'ARRAS</name>
      <address>
        <city>Arras</city>
        <zip>62022</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pauline LIONNE-HUYGHE, MD</last_name>
      <phone>+33 (0)3 21 21 10 10</phone>
      <email>pauline.lionne-huyghe@ch-arras.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service d'Hématologie, CHU Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrien CHAUCHET, MD</last_name>
      <phone>+33 (0)3 81 66 82 32</phone>
      <email>achauchet@chu-besancon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service d'Onco-radiolothérapie, Polyclinique Bordeaux Nord Aquitaine</name>
      <address>
        <city>Bordeaux</city>
        <zip>33300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier FITOUSSI, MD</last_name>
      <phone>+33 (0) 5 56 43 73 54</phone>
      <email>o.fitoussi@bordeauxnord.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fontanet BIJOU, MD</last_name>
      <phone>05 56 33 33 39</phone>
      <phone_ext>+33</phone_ext>
      <email>f.bijou@bordeaux.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Fontanet BIJOU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Pierre Oudot</name>
      <address>
        <city>Bourgoin-Jallieu</city>
        <zip>38302</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence LACHENAL, MD</last_name>
      <phone>+33 (0)4 69 15 73 29</phone>
      <email>flachenal@ch-bourgoin.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service d'Hématologie, Institut d'Hématologie de Basse Normandie</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gandhi DAMAJ, PhD</last_name>
      <phone>+33 (0) 2 31 27 25 36</phone>
      <email>damaj-gl@chu-caen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>METROPOLE SAVOIE - SITE CHAMBERY, place Lucien Biset,</name>
      <address>
        <city>Chambéry</city>
        <zip>73000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gian Matteo PICA, MD</last_name>
      <phone>0)4 79 96 50 50</phone>
      <email>gian-matteo.pica@ch-metropole-savoie.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Estaing, CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romain GUIEZE, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unité Hémopathies Lymphoïdes, Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne HAIOUN, PhD</last_name>
      <phone>+33 (0) 1 49 81 20 51</phone>
      <email>corinne.haioun@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Francois MITTERRAND</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>René-Olivier CASASNOVAS, MD</last_name>
      <phone>03 80 29 50 41</phone>
      <email>olivier.casasnovas@chu-dijon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Cédric ROSSI, MD</last_name>
      <phone>03 80 29 50 41</phone>
      <phone_ext>+33</phone_ext>
      <email>cedric.rossi@chu-dijon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Cédric ROSSI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service Hématologie, Centre Hospitalier de Dunkerque</name>
      <address>
        <city>Dunkerque</city>
        <zip>59140</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe FRUCHART, MD</last_name>
      <phone>+33 (0)3 28 28 55 29</phone>
      <email>christophe.fruchart@ch-dunkerque.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service Oncologie médicale, Groupe Hospitalier Mutualiste de Grenoble, Institut Daniel Hollard,</name>
      <address>
        <city>Grenoble</city>
        <zip>38028</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cécile LEYRONNAS, MD</last_name>
      <phone>+33 (0)4 76 28 52 32</phone>
      <email>c.leyronnas@ghm-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHD Vendée</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadine MORINEAU, MD</last_name>
      <phone>02 51 44 61 73</phone>
      <phone_ext>+33</phone_ext>
      <email>nadine.morineau@chd-vendee.fr</email>
    </contact>
    <investigator>
      <last_name>Nadine MORINEAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Hématologie Clinique, Centre Hospitalier Universitaire Michallon</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rémy GRESSIN, MD</last_name>
      <phone>+33 (0) 4 76 76 57 12</phone>
      <email>rgressin@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Victor Hugo</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katell LE DÛ, MD</last_name>
      <phone>+33 (0)2 43 47 94 93</phone>
      <email>k.ledu@cjb72.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Libourne</name>
      <address>
        <city>Libourne</city>
        <zip>33500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaelle LABOURE, MD</last_name>
      <phone>+33557553340</phone>
      <email>gaelle.laboure@ch-libourne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service Oncologie médicale, HOPITAL SAINT VINCENT-DE-PAUL</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandy AMORIM, MD</last_name>
      <phone>+33 (0)3 20 87 45 32</phone>
      <email>amorim.sandy@ghicl.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service des maladies du sang, Hôpital Claude Huriez, CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck MORSCHHAUSER, MD</last_name>
      <phone>+33 (0) 3 20 44 60 68</phone>
      <email>franck.morschhauser@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service Hématologie Clinique et Thérapie Cellulaire, CHU DE LIMOGES - HOPITAL DUPUYTREN,</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie ABRAHAM, MD</last_name>
      <phone>+33 (0)5 55 05 66 51</phone>
      <email>julie.abraham@chu-limoges.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Département d'Hématologie et Oncologie, Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laure LEBRAS, MD</last_name>
      <phone>+33 (0) 4 78 78 27 37</phone>
      <email>laure.lebras@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Département d'Hématologie Clinique, Hôpital Saint-Eloi,</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume CARTRON, PhD</last_name>
      <phone>+33 (0) 4 67 33 67 33</phone>
      <email>g-cartron@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service Hématologie, GH REGION MULHOUSE ET SUD ALSACE - HOPITAL EMILE MULLER,</name>
      <address>
        <city>Mulhouse</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard DRENOU, MD</last_name>
      <phone>+33 (0)3 89 64 75 21</phone>
      <email>drenoub@ghrmsa.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service d'Hématologie clinique, Centre Hospitalier Universitaire de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas GASTINNE, PhD</last_name>
      <phone>+33 (0) 2 40 08 32 71</phone>
      <email>thomas.gastinne@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Niort</name>
      <address>
        <city>Niort</city>
        <zip>79021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaëlle Olivier, MD</last_name>
      <phone>+33 (0)5 49 78 35 61</phone>
      <email>gaelle.olivier@ch-niort.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service Hématologie, Hôpital St Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine THIEBLEMONT, PhD</last_name>
      <phone>+33 (0) 1 42 49 98 37</phone>
      <email>catherine.thieblemont@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Haut-Lévêque</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamal-Krimo BOUABDALLAH, MD</last_name>
      <phone>05 57 65 65 11</phone>
      <phone_ext>+33</phone_ext>
      <email>krimo.bouabdallah@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Kamal-Krimo BOUABDALLAH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hervé Ghesquières, MD</last_name>
      <phone>04 78 86 43 40</phone>
      <phone_ext>+33</phone_ext>
      <email>herve.ghesquieres@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Alain Monnereau</last_name>
      <phone>05 56 33 33 33</phone>
      <phone_ext>+33</phone_ext>
      <email>A.Monnereau@bordeaux.unicancer.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Hervé Ghesquières, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Hématologie et Thérapie Cellulaire, Centre Hospitalier Universitaire de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphanie GUIDEZ, MD</last_name>
      <phone>+33 (0) 5 49 44 44 44</phone>
      <email>Stephanie.guidez@chu-poitiers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hématologie Clinique, CHU PONTCHAILLOU</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry LAMY DE LA CHAPELLE, PhD</last_name>
      <phone>+33 (0)2 99 28 42 91</phone>
      <email>thierry.lamy.de.la.chapelle@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service Hématologie, Centre Hospitalier de Roubaix - Hôpital Victor Provo</name>
      <address>
        <city>Roubaix</city>
        <zip>59056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence DETOURMIGNIES, MD</last_name>
      <phone>+33 (0)3 20 99 32 70</phone>
      <email>isabelle.plantier@ch-roubaix.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service Hématologie, UNIVERSITE DE ROUEN, CENTRE HENRI BECQUEREL</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice JARDIN, PhD</last_name>
      <phone>+33 (0)2 32 08 24 65</phone>
      <email>fabrice.jardin@chb.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service Hématologie, CH YVES LE FOLL</name>
      <address>
        <city>Saint-Brieuc</city>
        <zip>22027</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent LAUNAY, MD</last_name>
      <phone>+33 (0)2 96 01 70 82</phone>
      <email>vincent.launay@ch-stbrieuc.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service Hématologie, Institut Curie - Hôpital René HUGUENIN</name>
      <address>
        <city>Saint-Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carole SOUSSAIN, MD</last_name>
      <phone>+33 (0)1 47 11 15 15</phone>
      <email>carole.soussain@curie.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Département d'Hématologie Clinique et Thérapie Cellulaire, Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ludovic FOUILLET, MD</last_name>
      <phone>+33 (0)4 77 91 70 60</phone>
      <email>ludovic.fouillet@icloire.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luc-Matthieu FORNECKER, MD</last_name>
      <phone>03 88 12 76 79</phone>
      <phone_ext>+33</phone_ext>
      <email>luc-matthieu.fornecker@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Luc-Matthieu FORNECKER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loïc YSEBAERT, MD</last_name>
      <phone>05 31 15 63 51</phone>
      <phone_ext>+33</phone_ext>
      <email>ysebaert.loic@iuct-oncopole.fr</email>
    </contact>
    <investigator>
      <last_name>Loïc YSEBAERT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hématologie Clinique, CH DE BRETAGNE ATLANTIQUE</name>
      <address>
        <city>Vannes</city>
        <zip>56017</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine BONNET, MD</last_name>
      <phone>+33 (0)2 97 01 46 35</phone>
      <email>antoine.bonnet@ch-bretagne-atlantique.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 16, 2018</study_first_submitted>
  <study_first_submitted_qc>March 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2019</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lymphoma</keyword>
  <keyword>real life</keyword>
  <keyword>cohort</keyword>
  <keyword>epidemiology</keyword>
  <keyword>PRO</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

